Short Interest in PURE Bioscience (OTCMKTS:PURE) Declines By 88.9%

PURE Bioscience (OTCMKTS:PURE) was the recipient of a large decrease in short interest in the month of December. As of December 31st, there was short interest totaling 2,909 shares, a decrease of 88.9% from the December 15th total of 26,140 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 131,046 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 131,046 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold.

PURE Bioscience Price Performance

Shares of OTCMKTS PURE opened at $0.05 on Wednesday. PURE Bioscience has a 1 year low of $0.04 and a 1 year high of $0.21. The firm has a 50-day moving average of $0.05 and a 200 day moving average of $0.07. The stock has a market cap of $5.46 million, a P/E ratio of -1.63 and a beta of 0.59.

PURE Bioscience (OTCMKTS:PURE) last announced its quarterly earnings data on Wednesday, October 29th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $1.71 million for the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.